These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral. Shah MB; Martin JE; Schroeder TJ; First MR Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291 [No Abstract] [Full Text] [Related]
6. Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients. Loss GE; Brady L; Grewal HP; Siegel CT; Mead J; Bruce DS; Cronin DC; Woodle ES; Newell KA; Thistlethwaite JR; Millis JM Transplant Proc; 1998 Jun; 30(4):1435-6. PubMed ID: 9636581 [No Abstract] [Full Text] [Related]
7. [What significance has the C(2) value in the treatment with cyclosporin A?]. Pham VV; Stichtenoth DO; Frölich JC Dtsch Med Wochenschr; 2004 Mar; 129(13):706. PubMed ID: 15026970 [No Abstract] [Full Text] [Related]
8. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs Sandimmune. Choc MG Int J Dermatol; 1997 Dec; 36 Suppl 1():1-6. PubMed ID: 9466213 [No Abstract] [Full Text] [Related]
10. Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients. Crocker J; Renton K; Wade A; McLellan H; Acott P Transplant Proc; 1998 Aug; 30(5):2002-5. PubMed ID: 9723369 [No Abstract] [Full Text] [Related]
11. Generic substitution for cyclosporine: what should we be looking for in new formulations? Johnston A; Holt DW Transplant Proc; 1998 Aug; 30(5):1652-3. PubMed ID: 9723228 [No Abstract] [Full Text] [Related]
12. Lessons from the Neoral Global Database for renal transplantation. Helderman JH Transplant Proc; 1999 May; 31(3):1659-63. PubMed ID: 10331036 [No Abstract] [Full Text] [Related]
13. Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve. Belitsky P; Mahalati K; West K; Sketris I Transplant Proc; 1999 May; 31(3):1667-8. PubMed ID: 10331038 [No Abstract] [Full Text] [Related]
14. Conversion from regular cyclosporine to microemulsion cyclosporine following heart transplantation. Heroux AL; LeBlanc MH; Beaudoin D; Simard S; Coulombe DA; Gleeton O; Lemieux MD; Doyle DP Transplant Proc; 1996 Dec; 28(6):3145-8. PubMed ID: 8962219 [No Abstract] [Full Text] [Related]
15. The impact of cyclosporin formulation on clinical outcomes. Holt DW; Johnston A Transplant Proc; 2000 Nov; 32(7):1552-5. PubMed ID: 11119831 [No Abstract] [Full Text] [Related]
16. Optimization of cyclosporine therapy in renal transplantation. Ponticelli C Transplant Proc; 1998 Aug; 30(5):1718-20. PubMed ID: 9723254 [No Abstract] [Full Text] [Related]
17. Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients. Fisher RA; Pan SH; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; Lopez RR Transplant Proc; 1999; 31(1-2):394-5. PubMed ID: 10083157 [No Abstract] [Full Text] [Related]
18. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application? Haller GW; Winkler M; Bechstein WO; Oldhafer KJ; Ringe B; Maibücher A; Färber L; Pichlmayr R; Neuhaus P Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211 [No Abstract] [Full Text] [Related]
19. Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine. Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S Transplant Proc; 1998 Aug; 30(5):1760-1. PubMed ID: 9723270 [No Abstract] [Full Text] [Related]